Document:

Exhibit 10.1 

 

SETTLEMENT AGREEMENT

 

This settlement agreement (the “Agreement”) is entered
into as of April 22, 2014 (“Effective Date”), by and between Affymetrix, Inc., having a principal place of business
at 3420 Central Expressway, Santa Clara, California (“Affymetrix”) and Enzo Biochem, Inc. and Enzo Life Sciences, Inc.
(formerly known as Enzo Diagnostics, Inc.), having a principal place of business at 527 Madison Avenue, New York, New York (collectively
“Enzo”). Each of the foregoing entities is sometimes referred to as a “Party” and collectively as the “Parties.”

 

Affymetrix brought an action against Enzo in the United States
District Court, Southern District of New York, captioned Affymetrix, Inc. v. Enzo Biochem, Inc. et al., Case No 03-CV-08907
RJS. Enzo brought an action against Affymetrix in the United States District Court, Eastern District of New York, captioned Enzo
Life Sciences, Inc., formerly known as Enzo Diagnostics, Inc., v. Affymetrix, Inc., Case No. CV 03-5446, which was subsequently
transferred to the United States District Court, Southern District of New York, and captioned Enzo Life Sciences, Inc. v. Affymetrix,
Inc., Case No. 04-CV-01555 RJS (The cases, numbered 03-CV-08907 and 04-CV-01555 are collectively referred to as the “Actions”).
Affymetrix and Enzo mutually desire to resolve the differences between them regarding the Actions subject to the terms and conditions
of this Agreement.

 

For good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the Parties agree as follows:

 

ARTICLE I

DEFINITIONS

 

1.1 “Affiliate” means any entity
that directly or indirectly owns or controls, is owned or controlled by, or is under common ownership or control with a Party.
For the purposes of this definition, “ownership” or “control” mean: (a) possession, or the right to possession,
of at least 50% of the voting stock of a corporation; (b) the power to direct the management and policies of the entity; (c) the
power to appoint or remove a majority of the board of directors; or (d) the right to receive 50% or more of the profits or earnings.
With regard to Affymetrix, its Affiliates are listed in Exhibit 21 to its 10K for the fiscal year ended December 31, 2013.

 

ARTICLE
II

SETTLEMENT
AMOUNT

 

2.1 Affymetrix shall pay $5,100,000.00 as follows:
$4,335,000.00 to Enzo Biochem, Inc. and $765,000.00 to Greenberg Traurig, LLP by wire transfer (the “Settlement Payment”)
within five (5) business days of the Parties’ mutual execution and delivery of this Agreement and attached Stipulation of
Dismissal. Enzo Biochem, Inc., and Greenberg Traurig, LLP, shall acknowledge receipt of payment within no more than one business
day by email to Michael.Malecek@KayeScholer.com. Affymetrix shall hold the executed Stipulation of Dismissal in escrow and shall
file same within two (2) business days of acknowledgement by Enzo Biochem, Inc., and Greenberg Traurig, LLP of their receipt of
payment of the Settlement Payment. Affymetrix shall use the following wire transfer instructions:

    	1

    	

    

Enzo to receive $4,335,000 at:

 

	 	 	Citibank
	 	 	 
	For credit to the account of:	 	Enzo Biochem, Inc.
	 	 	 
	ABA routing number	 	21000089
	 	 	 
	Account #	 	119121150
	 	 	 
	Greenberg Traurig, LLP to receive $765,000 at:
	 
	 	 	Citibank NA
	 	 	201 S. Biscayne Blvd., Suite 3100
	 	 	Miami, Florida  33131 USA
	 	 	 
	For credit to the account of:	 	Greenberg Traurig
	 	 	 
	ABA routing number	 	266086554
	 	 	 
	Account #	 	3200175071
	 	 	 
	Reference:	 	Client/Matter # 067748.014500

 

ARTICLE III

RELEASES AND DISMISSAL OF ACTIONS

 

3.1 Affymetrix Release of Enzo.
Affymetrix, on behalf of itself and its Affiliates and all of their respective predecessors,
successors and assigns, releases, acquits, and forever discharges Enzo and its Affiliates and all of
their respective predecessors, successors, assigns, officers, directors, managers, members, employees, agents, insurers, servants,
experts, consultants, and attorneys (the “Enzo Released Parties”) from all liabilities, actions, causes of action,
claims or demands, losses, damages, attorneys’ fees, court costs, or any other form of claim or compensation related to or
arising under any claim or counterclaim that Affymetrix now has, ever had, or could in the future have (but for this release) against
the Enzo Released Parties, asserted in, arising out of, resulting from, or relating in any way to the Actions.

 

3.2 Enzo
Release of Affymetrix. Enzo on behalf of itself and its Affiliates and all of their respective predecessors, successors
and assigns, releases, acquits, and forever discharges Affymetrix and its Affiliates and all of their
respective predecessors, successors, assigns, officers, directors, managers, members, employees, agents, insurers, servants, experts,
consultants, and attorneys (the “Affymetrix Released Parties”) from all liabilities, actions, causes of action, claims
or demands, losses, damages, attorneys’ fees, court costs, or any other form of claim or compensation related to or arising
under any claim or counterclaim that Enzo now has, ever had, or could in the future have (but for this release) against the Affymetrix
Released Parties, asserted in, arising out of, resulting from, or relating in any way to the Actions.

    	2

    	

    

3.3 Delaware
Litigation. For avoidance of doubt, neither Enzo’s release of Affymetrix nor Affymetrix’s release of Enzo
includes the litigation currently pending in the District of Delaware, captioned Enzo Life Sciences v. Affymetrix, Inc.,
Case No. 12-cv-433-LPS, and any of the claims there asserted, in which Enzo alleges, among other things, that Affymetrix has and
continues to infringe on U.S. Patent No. 7,064,197 (the “Delaware Litigation”). The Parties agree that no rulings in
the Actions shall have preclusive effect on the Delaware Litigation.

 

3.4 Releases.
The releases specifically provided in this Agreement include an express, informed, knowing, and voluntary waiver and relinquishment
to the fullest extent permitted by law. In this connection, the Parties acknowledge that they may have sustained damages, losses,
costs, or expenses that are presently unknown and unsuspected and that such damages, losses, costs, or expenses as may have been
sustained may give rise to additional damages, losses, costs, or expenses in the future. The Parties acknowledge, and waive any
rights under, California Civil Code Section 1542, which provides as follows:

 

“A
GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME
OF EXECUTING THE RELEASE, WHICH, IF KNOWN BY HIM OR HER, MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.”

 

or
by any similar or comparable law of any state, territory or jurisdiction, foreign or domestic, including the United States and
federal, state, county or local jurisdiction which is similar, comparable, or equivalent to Section 1542 of the California Civil
Code.

 

3.5 Agreement Obligations Not Released. Notwithstanding
anything to the contrary herein, the Parties reserve all rights and remedies, including damages and equitable relief, for breach
of this Agreement and nothing herein releases any Party from its respective obligations under this Agreement or prevents any Party
from enforcing the terms and conditions of this Agreement against the other Party.

 

3.6 Joint Stipulation of Dismissal with Prejudice. Affymetrix
will file a Joint Stipulation of Dismissal with Prejudice in the Southern District of New York in the form set forth in Exhibit
A attached hereto in accordance with Section 2.1. The Parties shall promptly proceed with any
and all additional procedures needed to dismiss with prejudice the Actions including any modifications to the forms to comply with
any local rules or procedures regarding the entry of stipulated dismissals. The Parties acknowledge and agree that this Agreement
is enforceable according to its terms with respect to final dismissal with prejudice of the Actions.

 

3.7 No Effect On Other Actions. This Agreement, including
the releases herein, does not affect any other pending action by Enzo as listed in Exhibit B attached hereto.

 

ARTICLE
IV

REPRESENTATIONS,
WARRANTIES, AND DISCLAIMERS

 

4.1  Mutual Representations and
Warranties. Each Party represents and warrants to the other that: (a) each person executing this Agreement on its behalf has
full authority to enter into

    	3

    	

    

this Agreement; (b) it enters into this Agreement
of its own free will and accord, upon advice of its own legal counsel; (c) it has the authority to enter into and to perform or
to cause performance of its obligations under this Agreement; (d) the execution and delivery of this Agreement and the actions
contemplated hereby have been duly authorized by all necessary corporate action; (e) this Agreement constitutes a valid and binding
obligation, enforceable in accordance with its terms; (f) no further approval is needed to make this Agreement valid, binding,
and enforceable; and (g) the execution and delivery of this Agreement will not violate, conflict with, or result in a breach of
the terms of any agreement by which such Party is bound or of any applicable statute, regulation, rule, or other law.

 

4.2 No Admission. This Agreement
is made in connection with a full, final, and complete satisfaction and compromise of disputed claims and matters. Neither this
Agreement nor any action taken in connection with this Agreement or pursuant to it constitutes an admission by any Party or by
any other Party that any conduct or action was unlawful or in violation of any contract, agreement, understanding, custom, or obligation
among or between the Parties, or constituted any wrongdoing whatsoever.

 

ARTICLE V

PUBLIC DISCLOSURE

 

5.1  Public Disclosure. The Parties
agree that any public disclosure of the existence and terms of this Agreement will be limited to the extent it is believed to be
required to do so by law, rule, regulation or legal process, including by any stock exchange, the NASDAQ National Market or the
rules and regulations of the United States Securities Exchange Commission or any applicable state securities regulators. Affymetrix
has received and reviewed the press release and draft form 8-K attached as Exhibit C and consents to the distribution and filing
thereof.

 

ARTICLE VI

MISCELLANEOUS

 

6.1  Notices. All required
communications under this Agreement shall be in writing, sent to the Party at its address below, or as otherwise designated by
the Party in accordance with this provision, and duly given or made: (a) on the date delivered in person; (b) on the date transmitted
by electronic mail, if confirmation is received from the recipient; (c) three days after deposit in the mail if sent by certified
U.S. mail postage prepaid, return receipt requested; or (d) one day after deposit with a nationally recognized overnight carrier
service with charges prepaid.

    	4

    	

    

	 	If to Affymetrix:	Affymetrix, Inc.
	 	 	3420 Central Expressway
	 	 	Santa Clara, California  95051
	 	 	Attention:  Siang Chin
	 	 	siang_chin@affymetrix.com
	 	 	 
	 	If to Enzo:	Enzo Biochem
	 	 	527 Madison Avenue
	 	 	New York, New York 10022
	 	 	Attention: Barry Weiner
	 	 	bweiner@enzo.com

 

6.2 Governing Law/Entire Agreement.
This Agreement shall be governed by the laws of the state of New York without regard to any conflict-of-laws provisions. This
Agreement, including its exhibits, constitutes the entire agreement between the Parties with respect to the subject matter hereof,
and supersedes all other previous and contemporaneous agreements, understandings, negotiations, discussions, offers, and acceptances
with respect to such subject matter. This Agreement may not be modified except in writing signed by authorized representatives
of the Parties. The delay or failure to assert a right or to insist upon compliance with any term or condition of this Agreement
shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition. A valid
waiver must be executed in writing and signed by the Party granting the waiver. Each Party acknowledges that it was provided an
opportunity to seek advice of counsel and as such this Agreement shall not be strictly construed against the drafter. This Agreement
shall be binding on and inure to the benefit of each of the Parties and their successors and assigns.

 

6.3 Severability. The provisions
of this Agreement are severable, and if any provision of this Agreement is determined to be invalid or unenforceable under any
controlling body of law, such invalidity or non-enforceability shall not in any way affect the validity or enforceability of the
remaining provisions or the validity or enforceability of such provision in any jurisdiction where valid and enforceable. Any invalid
or unenforceable provision will be reformed by the Parties to effectuate their intent as evidenced on the Effective Date. The Parties
execute this valid and binding agreement in one or more counterparts, each of which shall be deemed an original and all of which,
taken together, shall constitute one and the same instrument.

    	5

    	

    

	AFFYMETRIX, INC.	 	ENZO BIOCHEM, INC.
	 	 	 	 	 	 
	By:	/s/ Siang Chin	 	By:	/s/ Elazar Rabbani	 
	Siang Chin	Elazar Rabbani
	Senior Vice President and General Counsel	 
	 	 	 	 
	Dated:	April 22, 2014	 	Dated:	April 22, 2014	 
	 	 	 	 	 	 
	 	 	 	ENZO LIFE SCIENCES, INC.
	 	 	 	 	 	 
	 	 	 	By:	/s/ Elazar Rabbani	 
	 	 	 	 	 	 
	 	 	 	Dated:  	April 22, 2014	 

    	6

    	

    

Exhibit
a

    	7

    	

    

UNITED STATES DISTRICT COURT

SOUTHERN DISTRICT OF NEW YORK

	
         

        ENZO LIFE SCIENCES, INC.,

         

        Plaintiff,

         

        v.

         

        AFFYMETRIX, INC.,

         

        Defendant.

         
	
        )

)

)

)

)

)

)

)

)

 

)

	
        CIVIL ACTION NO. 04-CV-1555 (RJS)

         

         

         

         

        STIPULATION OF DISMISSAL

         

         

         

         

        CIVIL ACTION NO. 03-CV-8907 (RJS)

         

	
         

        AFFYMETRIX, INC.,

         

        Plaintiff,

         

        v.

         

        ENZO BIOCHEM, INC. and

        ENZO LIFE SCIENCES, INC.,

         

        Defendants.

         

	
        )

)

)

)

)

)

)

)

)

)

)

 

IT IS HEREBY STIPULATED
AND AGREED that all claims by Enzo Life Sciences, Inc. (formerly known as Enzo Diagnostics, Inc.) against Affymetrix, Inc. shall
be, and hereby are, dismissed with prejudice and without fees and costs;

 

IT IS FURTHER STIPULATED
AND AGREED that all claims by Affymetrix, Inc. against Enzo Biochem, Inc. and Enzo Life Sciences, Inc. (formerly known as Enzo
Diagnostics, Inc.) shall be, and hereby are, dismissed with prejudice and without fees and costs;

 

IT IS FURTHER STIPULATED
AND AGREED that this Stipulation is without prejudice to Enzo Biochem, Inc. and Enzo Life Sciences, Inc.’s rights to appeal
in any other action;

 

IT IS FURTHER STIPULATED
AND AGREED that this Stipulation may be executed in separate multiple counterparts, each of which shall be deemed to be an original.
Signatures

    	8

    	

    

provided through email or facsimile are
deemed to be the equivalent of originals for filing purposes.

 

	Dated: 	April 22, 2014
	 	New York, New York

 

	GREENBERG TRAURIG, LLP 	 	KAYE SCHOLER,
LLP
	 	 	 	 	 
	By: 	/s/ Ronald D. Lefton 	 	By:	  /s/ Michael J. Malecek
	 	Ronald D. Lefton	 	 	Michael J. Malecek
	 	leftonr@gtlaw.com	 	 	michael.malecek@kayescholer.com
	 	Karen Y. Bitar	 	 	Peter E. Root
	 	bitark@gtlaw.com	 	 	peter.root@kayescholer.com
	Attorneys for Plaintiff/Defendants	 	Attorneys for Plaintiff/Defendant
	Enzo Life Sciences, Inc. and	 	Affymetrix, Inc.
	Enzo Biochem, Inc.	 	3000 El Camino Real
	200 Park Avenue	 	2 Palo Alto Square, Suite 400
	New York, New York 10166	 	Palo Alto, CA 94306
	(212) 801-9200	 	(650) 319-4500
	 	 	 
	ENZO LIFE SCIENCES, INC.	 	AFFYMETRIX, INC.
	 	 	 	 	 
	By:	/s/ Elazar Rabbani	 	By:	/s/ Siang Chin
	 	Name: Elazar Rabbani	 	 	Name: Siang Chin
	 	Title:   Chairman	 	 	Title:   Senior Vice President and General Counsel
	 	 	 	 	 
	ENZO BIOCHEM, INC.	 	 	 
	 	 	 	 	 
	By:	/s/ Elazar Rabbani	 	 	 
	 	Name: Elazar Rabbani	 	 	 
	 	Title:   Chairman	 	 	 

    	9

    	

    

Exhibit
B

    	10

    	

    

	Caption	 	Court	 	Docket No.
	 	 	 	 	 
	Enzo Biochem, Inc., et al v. Molecular Probes, Inc.	 	S.D.N.Y.	 	03-cv-03816
	Enzo Biochem, Inc., et al v. Perkinelmer, Inc., et al	 	S.D.N.Y.	 	03-cv-03817
	Roche Diagnostics GMBH, et al v. Enzo Biochem, Inc. et al	 	S.D.N.Y.	 	04-cv-04046
	Enzo Life Sciences Inc. v. Gen-Probe, Inc.	 	D. Del.	 	12-cv-00104
	Enzo Life Sciences Inc. v. Life Technologies Corp.	 	D. Del.	 	12-cv-00105
	Enzo Life Sciences Inc. v. Roche Molecular Systems Inc., et al	 	D. Del.	 	12-cv-00106
	Enzo Life Sciences Inc. v. Hologic, Inc.	 	D. Del.	 	12-cv-00276
	Enzo Life Sciences Inc. v. Abbott Laboratories, et al	 	D. Del.	 	12-cv-00274
	Enzo Life Sciences Inc. v. Becton, Dickinson & Company, et al	 	D. Del.	 	12-cv-00275
	Enzo Life Sciences Inc. v. Illumina, Inc.	 	D. Del.	 	12-cv-00435
	Enzo Life Sciences Inc. v. Adipogen Corp., et al	 	D. Del.	 	11-cv-00088
	Enzo Life Sciences Inc. v. Agilent Technologies, Inc.	 	D. Del.	 	12-cv-00434
	Enzo Life Sciences Inc. v. Siemens Healthcare Diagnostics, Inc.	 	D. Del.	 	12-cv-00505ex101.htm

EXHIBIT 10.1

 

AMENDMENT NO. 1

TO

LIVEWIRE ERGOGENICS, INC.

2013 STOCK INCENTIVE PLAN

 

WHEREAS, in May of 2013 the Company adopted its 2013 Stock Incentive Plan, filed with the Securities & Exchange Commission on May 3, 2013 (the “Plan”), covering 5,000,000 shares of Common Stock; and

 

WHEREAS, on April 22, 2014, the Board of Directors of the Company pursuant to Section 9 of the Plan determined to amend the Plan to increase the number of shares authorized for issuance under the Plan to 15,000,000 shares (the “Amendment”);

WHEREAS, on April 22, 2014, by requisite vote of the stockholders of the Company, the Amendment was approved;

NOW, THEREFORE, the Plan is hereby amended as follows:

 

1. The first sentence of Section 4(b) of the Plan is hereby deleted in its entirety and superseded and replaced as follows:

“(b) Number of Shares.  Subject to adjustment as provided in Section 5(i) of the Plan, the total number of shares of Stock which may be purchased or granted directly by Options, Stock Awards or Restricted Stock Purchase Offers, or purchased indirectly through exercise of Options granted under the Plan shall not exceed fifteen million (15,000,000).”

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00229-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00229-of-00352.parquet"}]]